Capabilities of cytostatic agents usage in ophthalmology

Abstract

Antineoplastic drugs are increasingly used in the treatment of diseases of the vision organ. However, practicing ophthalmologists often deal with lack of information about the choice of drugs with anticancer effect, their mechanism of action, dosage, route of administration, potential side effects including their prevention. Mechanism of action is presented for the most commonly used immunosuppressants in ophthalmology (such as metabolic antagonists, alkylation agents, antineoplastic antibiotics, monoclonal antibodies). Efficiency and routes of administration are described for cytostatics used for the treatment of intraocular tumors (retinoblastoma), for prevention and treatment of proliferative syndrome in ophthalmosurgery complicating the surgery for glaucoma, pterigium and refractive corneal procedures, and presenting the pathogenetic basis of proliferative vitreoretinopathy and posterior lens capsule opacity. Possible local side effects of immunosupressors in ocular surgery are presented (epithelial and suture defects, hemorrhagic choroidal detachment, cataract progression, endophthalmitis, malignant glaucoma, toxic effect on the ciliary body, keratopathy, hypertensive maculopathy). Also, the issue of the use of cytostatics and immunodepressants for acute and chronic inflammatory eye diseases is discussed (for example, for uveitis, filamentary ke­ratitis, allergic blepharoconjunctivitis, allergic conjunctivitis and spring ophthalmia, adenoviral keratoconjunctivitis, rosacea keratitis, ocular pemphigoid, recurrent chalazion, scleritis, episcleritis, painful bullous keratopathy, state after keratoplasty and refractive surgery of ocular fibrous capsule). Special attention was paid to the eye neovascularization and common use of intravitreal injections of monoclonal antibodies (ranibizumab, aflibercept) for premature infants’ retinopathy, choroidal neovascularization of various origin (in trauma, myopia, histoplasmosis), neovascular form of age-related macular dystrophy, secondary neovascular glaucoma, proliferative diabetic retinopathy and diabetic macular edema. Need for search of new more effective and safe medicines with antineoplastic and immunodepressive action is emphasized for ophthalmology, eye surgery and medicine in general.

Keywords

cytostatic agents / ophthalmology / proliferative syndrome / ocular angiogenesis / autoimmune uveitis / dry eye syndrome

References

[1] Skil R.T. Protivoopukholevaya khimioterapiya. Rukovodstvo. (Antineoplastic chemiotharepy. Guide.) Ed. by R.T. Skil, per. s angl. V.S. Pokrovskogo, pod red. S.V. Orlova. M.: GEOTAR-Media. 2011; 1032 p. (In Russ.)

[2] Противоопухолевая химиотерапия. Руководство. Под ред. Р.Т. Скила, пер. с англ. В.С. Покровского, под ред. С.В. Орлова. М.: ГЭОТАР-Медиа. 2011; 1032 c.

[3] Germanova V.N., Volzhanin A.V., Zolotarev A.V. et al. Cyclosporin A in surgical treatment of glaucoma: prospects and opportunities. Natsionalʹnyy zhurnal glauлoma. 2017; 16 (2): 92–100. (In Russ.)

[4] Германова В.Н., Волжанин А.В., Золотарёв А.В. и др. Циклоспорин А в хирургическом лечении глаукомы: перспективы и возможности. Нац. ж. глаукома. 2017; 16 (2): 92–100.

[5] Chuchalin A.G. Innovative medicines of 21st century. Vestnik Rossiyskoy Akademii Nauk. 2016; 86 (6): 480–483. (In Russ.)

[6] Чучалин А.Г. Инновационные лекарственные средства XXI века. Вестн. РАН. 2016; 86 (6): 480–483. DOI: 10.7868/S0869587316060050.

[7] Tolʹkova E.S. Production of monoclonal antibodies. Mezhdunarodnyy nauchno-issledovatelʹskiy zhurnal. 2015; (6-2): 36–40. (In Russ.)

[8] Толькова Е.С. Получение моноклональных антител. Международ. науч.-исслед. ж. 2015; (6-2): 36–40.

[9] Chekhova T.A., Cher­nykh V.V. Ocular Rosacea — etiology, pathogenesis, new methods of treatment. Oftalʹmokhirurgiya. 2016; (2): 54–58. (In Russ.)

[10] Чехова Т.А., Черных В.В. Офтальморозацеа — этиология, патогенез, новые подходы к терапии. Офтальмохирургия. 2016; (2): 54–58. DOI: 10.25276/0235-4160-2016-2-54-58.

[11] Chan H., Gallie B., Munier F., Beck Popovic M. Chemotherapy for retinoblastoma. Ophthalmol. Clin. North Am. 2005; 18 (10): 55–63. DOI: 10.1016/j.ohc.2004.11.002.

[12] Saakyan S.V. Modern treatment of retinoblastoma. Rossiyskiy oftalʹmologicheskiy zhurnal. 2008: 1: 33–38. (In Russ.)

[13] Саакян С.В. Современные подходы к лечению ретинобластомы. Рос. офтальмол. ж. 2008; 1: 33–38.

[14] Frederici T.J. Intravitreal injections: AAO’s Focal Points. Clin. Modules Ophthalmologists. 2009; 27 (8): 1–12.

[15] Bobrova N.F., Sorochinskaya T.A. Retinoblastoma intravitreal chemotherapy. Oftalʹmologicheskiy zhurnal. 2015; (3): 59–68. (In Russ.)

[16] Боброва Н.Ф., Сорочинская Т.А. Интравитреальная химеотерапия ретинобластомы. Офтальмол. ж. 2015; (3): 59–68. DOI: 10.31288/oftalmolzh201535968.

[17] Russkov K.N., Zolotarev A.V., Milyudin E.S. Pharmaceutical composition for prophylaxis of cell reaction ‘Mitomycin O’. Prakticheskaya meditsina. 2012; (4): 260–262. (In Russ.)

[18] Руссков К.Н., Золотарёв А.В., Милюдин Е.С. Фармацевтическая композиция для профилактики пролиферативной клеточной реакции «Митомицин-О». Практ. мед. 2012; (4): 260–262.

[19] Medvedev M.A., Dikambaeva M.K., Mamytova B.M., Ehrmekova A.Eh. Prospects of angiogenesis inhibitors usage in ophthalmology (preliminary report). Vestnik nauki i obrazovaniya. 2017; (3): 106–108. (In Russ.)

[20] Медведев М.А., Дикамбаева М.К., Мамытова Б.М., Эрмекова А.Э. Перспективы применения ингибиторов ангиогенеза в офтальмологии (предварительное сообщение). Вестн. науки и образования. 2017; (3): 106–108.

[21] Holló G. Wound healing and glaucoma surgery: Modulating the scarring process with conventional antimetabolites and new molecules. Dev. Ophthalmol. 2017; 59: 80–89. DOI: 10.1159/000458488.

[22] Petrov S.Yu., Shmyreva V.F., Antonov A.A. The method of cytostatic therapy for scarring prophylaxis after penetrating glaucoma surgery. Patent for invention RF №2336061. Bulletin issued on 01.03.2007. (In Russ.)

[23] Петров С.Ю., Шмырева В.Ф., Антонов А.А. Способ проведения цитостатической терапии для профилактики избыточного рубцевания после проникающей антиглаукоматозной операции. Патент на изобретение РФ №2336061. Бюлл. от 01.03.2007.

[24] Cui Q.N., Hsia Y.C., Lin S.C. et al. Effect of Mitomycin C and 5-flurouracil adjuvant therapy on the outcomes of Ahmed glaucomavalve implantation. Clin. Exp. Ophthalmol. 2017; 45 (2): 128–134. DOI: 10.1111/ceo.12811.

[25] Shmyreva V.F., Petrov S.Yu., Antonov A.A., Pimenidi M.K. Early controlled cytostatic therapy after glaucoma surgery. Vestnik oftalʹmologii. 2007; (1): 12–13. (In Russ.)

[26] Шмырева В.Ф., Петров С.Ю., Антонов А.А., Пимениди М.К. Контролируемая цитостатическая терапия в ранние сроки после антиглаукоматозной хирургии. Вестн. офтальмол. 2007; (1): 12–13.

[27] Medvedev I.B., Slonimskiy A.Yu., Falkut O.S., Dolgiy S.S. Prophylaxis of scarring after glaucoma surgery. Oftalʹmologiya. 2011; 89 (4): 8–12. (In Russ.)

[28] Медведев И.Б., Слонимский А.Ю., Фалкут О.С., Долгий С.С. Методы профилактики избыточного рубцевания при антиглаукоматозных операциях. Офтальмология. 2011; 8 (4): 8–12.

[29] Rascheskov A.Yu., Loskutov I.A. Modern me­thods of refractory glaucoma surgery (literature review). Oftalʹmologiya. 2012; 9 (1): 4–9. (In Russ.)

[30] Расчёсков А.Ю., Лоскутов И.А. Современные технологии хирургического лечения рефрактерной глаукомы (обзор литературы). Офтальмология. 2012; 9 (1): 4–9.

[31] Panarelli J.F., Vinod K., Huang G., Sidoti P.A. Transconjunctival revision with Mitomycin-C following failed trabeculectomy. J. Glaucoma. 2016; 25 (7): 618–622. DOI: 10.1097/IJG.0000000000000408.

[32] Garris W.J., Le C., Zurakowski D., Ayyala R.S. Comparison of surgical outcomes between canaloplasty and trabeculectomy with Mitomycin C at 2-year follow-up: A longitudinal cohort study. Indian J. Ophthalmol. 2018; 66 (1): 66–70. DOI: 10.4103/ijo.IJO_543_17.

[33] Poryadin V.R., Dostovalov S.M., Sen­chenko N.Ya., Yurʹeva T.N. Prophylaxis of recurrent progressive pterigium. Prakticheskaya meditsina. 2012; (4): 115–117. (In Russ.)

[34] Порядин В.Р., Достовалов С.М., Сенченко Н.Я., Юрьева Т.Н. Меры профилактики рецидива первичного прогрессирующего птеригиума. Практ. мед. 2012; (4): 115–117.

[35] Kam K.W., Kwok R.P., Belin M.W., Young A.L. Long-term density changes in corneal layers after primary pterygium excision with topical Mitomycin-C. Cornea. 2016; 35 (8): 1093–1096. DOI: 10.1097/ICO.0000000000000880.

[36] Da Costa Paula C., Julio G., Campos P. et al. Effects of Mitomycin C in early conjunctival inflammation after pterygium surgery. Curr. Eye Res. 2017; 42 (5): 696–700. DOI: 10.1080/02713683.2016.1236965.

[37] Khan F.A., Awais M., Niazi Sh.P. et al. Effectiveness of preoperative subconjunctival injection of Mitomycin-C in primary pterygium surgery. J. Coll. Physicians Surg. Pak. 2017; 27 (2): 88–91. PMID: 28292385.

[38] Gum S.I., Kim Y.H., Jung J.C. et al. Cyclosporine A inhibits TGF-β2-induced myofibroblasts of primary cultured human pterygium fibroblasts. Biochem. Biophys. Res. Commun. 2017; 482 (4): 1148–1153. DOI: 10.1016/j.bbrc.2016.12.002.

[39] Kudryashova E.V., Malʹtsev D.S. Topical 0.05% Cyclosporin usage as additional treatment after LASIK. Oftalʹmokhirurgiya. 2015; (3): 69–74. (In Russ.)

[40] Кудряшова Е.В., Мальцев Д.С. Местное применение 0,05% циклоспорина А в качестве вспомогательной терапии при LASIK. Офтальмохирургия. 2015; (3): 69–74. DOI: 10.25276/0235-4160-2015-3-69-74.

[41] Anumanthan G., Sharma A., Waggoner M. et al. Efficacy and safety comparison between suberoylanilide hydroxamic acid and Mitomycin C in reducing the risk of corneal haze after PRK treatment in vivo. J. Refractive Surg. 2017; 33 (12): 834–839. DOI: 10.3928/1081597X-20170921-02.

[42] Bayyrkhanova A.O., Botabekova T.K., Semenova Yu.M. et al. Physicochemical properties of intravitreal implant based on chitosan/polyvinil spirit saturated with 5-flurouracil. Sovremennye tekhnologii v meditsine. 2017; 9 (3): 102-–09. (In Russ.)

[43] Байырханова А.О., Ботабекова Т.К., Семёнова Ю.М. и др. Физико-химические свойства интравитреального имплантата на основе хитозана и полиэтилового спирта, насыщенного 5-фторурацилом. Соврем. технол. в мед. 2017; 9 (3): 102–109. DOI: 10.17691/stm2017.9.3.14.

[44] Bikbov M.M., Akmir­zaev A.A. Methods of postoperative posterior lens capsule opacity prophylaxis (literature review)). RMZH. Klini­ches­kaya oftalʹmologiya. 2011; (2): 81–83. (In Russ.)

[45] Бикбов М.М., Акмирзаев А.А. Методы про­фи­лактики и лечения послеоперационного помутнения зад­ней капсулы хрусталика (обзор литературы). РМЖ. Клин. офтальмол. 2011; (2): 81–83.

[46] Shokouhi-Rad S., Alizadeh R., Daneshvar R. Iatrogenic bleb formation and hypotony maculopathy following pterygium surgery with Mitomycin-C. J. Ophthalmic. Vis. Res. 2015; 10 (3): 345–347. DOI: 10.4103/2008-322X.170341.

[47] Yanai R., Takeda A., Yoshimura T., Sonoda K.H. Pathophysiology and new treatment of uveitis. Nihon Rinsho Meneki Gakkai Kaishi. 2014; 37 (2): 74–82. DOI: 10.2177/jsci.37.74.

[48] Hornbeak D.M., Thorne J.E. Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention. Taiwan J. Ophthalmol. 2015; 5 (4): 156–163. DOI: 10.1016/j.tjo.2015.03.004.

[49] Lebedev O.I., Surov A.V., Matnenko T.Yu., Salikhov M.M. Immunotherapy of uveitis associated with systemic diseases. RMZH. Klinicheskaya oftalʹmologiya. 2013; (2): 69–71. (In Russ.)

[50] Лебедев О.И., Суров А.В., Матненко Т.Ю., Салихов М.М. Иммунотерапия увеитов, ассоциированных с системными заболеваниями. РМЖ. Клин. офтальмол. 2013; (2): 69–71.

[51] Smith W.M. Cyclosporine: A historical perspective on its role in the treatment of noninfectious uveitis. J. Ocul. Pharmacol. Ther. 2017; 33 (4): 247–262. DOI: 10.1089/jop.2016.0155.

[52] Siak J., Chee S.P. Cytomegalovirus anterior uveitis following topical Cyclosporine A. Ocul. Immunol. Inflamm. 2017; 27: 1–4. DOI: 10.1080/09273948.2017.1306083.

[53] Levy O., Labbé A., Borderie V. et al. Topical cyclosporine in ophthalmology: Pharmacology and clinical indications. J. Fr. Ophtalmol. 2016; 39 (3): 292–307. DOI: 10.1016/j.jfo.2015.11.008.

[54] Labbé A., Baudouin C., Ismail D. et al. Pan-European survey of the topical ocular use of cyclosporine A. J. Fr. Ophtalmol. 2017; 40 (3): 187–195. DOI: 10.1016/j.jfo.2016.12.004.

[55] Maychuk D.Yu., Vasilʹeva O.A., Shokirova M.M. 0.05% Cyclosporin usage in ocular surface diseases. Vestnik oftalʹmologii. 2014; 130 (2): 68–71. (In Russ.)

[56] Майчук Д.Ю., Васильева О.А., Шокирова М.М. Применение 0,05% циклоспорина при различных заболеваниях глазной поверхности. Вестн. офтальмол. 2014; 130 (2): 68–71.

[57] Kudryashova Yu.I. Modern methods of immune-mediated form of dry eye syndrome treatment. RMZH. Klinicheskaya oftalʹmologiya. 2010; (1): 16–20. (In Russ.)

[58] Кудряшова Ю.И. Современные подходы к терапии иммуноопосредованной формы синдрома «сухого глаза». РМЖ. Клин. офтальмол. 2010; (1): 16–20.

[59] Alonso A., Bignone M.L., Brunzini M., Brunzini R. Ocular autoimmune pemphigoid and cyclosporin A. Allergol. Immunopathol. (Madr.). 2006; 34 (3): 113–115. DOI: 10.1157/13088180.

[60] Surguch V.K., Erichev V.P. Changes of anterior eye segment new vessels after antiangiogenic therapy (angiographic research). Glaukoma. 2013; 3 (1): 48–52. (In Russ.)

[61] Сургуч В.К., Еричев В.П. Изменение новообразованных сосудов переднего отрезка глаза после антиангиогенной терапии (ангиографическое исследование). Глаукома. 2013; 3 (1): 48–52.

[62] Alpatov S.A. Angiogenesis blockers for the eye diseases treatment. Klinicheskaya oftalʹmologiya. 2015; 15 (4): 196–200. (In Russ.)

[63] Алпатов С.А. Блокаторы ангиогенеза в лечении глазных заболеваний. Клин. офтальмол. 2015; 15 (4): 196–200.

[64] Chua B.E., Nguyen D.Q., Qin Q. et al. Bleb vascularity following post-trabeculectomy subconjunctival bevacizumab: a pilot study. Clin. Exp. Ophthalmol. 2012; 40 (8): 773–779. DOI: 10.1111/j.1442-9071.2012.02798.x.

[65] Radzhabova A.B., Karim-Zade Kh.D. Diagnostics, treatment and prophylaxis of premature infants retinopathy. Nauka molodykh. 2014; (1): 114–123. (In Russ.)

[66] Раджабова А.Б., Карим-Заде Х.Д. Диагностика, лечение и профилактика ретинопатии недоношенных. Наука молодых. 2014; (1): 114–123.

[67] Gupta N., Mansoor S., Sharma A. et al. Diabetic re­tinopathy and VEGF. Open Ophthalmol. J. 2013; 7: 4–10. DOI: 10.2174/1874364101307010004.

[68] Holz F.G., Tadayoni R., Beatty S. et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br. J. Ophthalmol. 2014; 99 (2): 220–226. DOI: 10.1136/bjophthalmol-2014-305327.

RIGHTS & PERMISSIONS

Belousova N.Y., Poltanova T.I.